EORTC Quality of Life Measurement Strategies in Progressive Cancer
Launched by UNIVERSITY OF LEEDS · Feb 18, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "EORTC Quality of Life Measurement Strategies in Progressive Cancer," aims to improve how we understand and measure the quality of life for people diagnosed with cancer who are experiencing disease progression. Quality of life refers to how well patients are feeling and functioning during their treatment. Researchers want to learn from patients, their caregivers, and healthcare professionals about the best ways to assess this quality of life, including how often these assessments should happen and how to keep participants engaged in the study over time.
To participate in this study, adults over 18 years old must have a confirmed cancer diagnosis and be facing a worsening of their condition, with a prognosis of less than three years. Caregivers, like family members or close friends of these patients, can also take part. Participants will be interviewed twice to see if their feelings and preferences change as time goes on. This research is important because it will help improve how we gather information about patients' experiences, which can lead to better healthcare decisions and treatments. The trial is not yet recruiting participants, but it will be conducted across various locations in Europe.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PATIENT- Adult (\> 18 years of age)
- • Histologically proven or radiologically diagnosed cancer
- • Clinical and/or radiological progressive disease according to RECIST criteria
- • Poor prognosis, i.e. expected survival time \<3 years according to the treating physician PROXIES - Adult (\> 18 years of age)
- • Partner, relative or close friend of a patient who is eligible according to the criteria specified above
- Exclusion Criteria:
- • Participants without understanding of the official language of the country in which they live
- • Participants with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper providing informed consent for research participation
About University Of Leeds
The University of Leeds is a prestigious research institution located in the United Kingdom, renowned for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, the University of Leeds leverages its diverse expertise and collaborative environment to facilitate high-quality clinical studies that aim to improve health outcomes and contribute to the scientific community. The university fosters interdisciplinary partnerships, ensuring rigorous methodologies and ethical standards in its research initiatives. By integrating cutting-edge technologies and a patient-centered approach, the University of Leeds plays a vital role in translating research findings into practical applications for healthcare improvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported